术中及术前化疗干预对进展期胃恶性肿瘤手术患者p53、ki-67表达及预后影响的比较

doi:10.3969/j.issn.1000-8535.2017.05.002

摘要/Abstract

摘要： 目的观察比较术中及术前化疗干预对进展期胃恶性肿瘤手术患者p53、ki-67表达及预后的影响,为临床化疗时间的选择提供理论依据。方法自2014年8月—2015年5月,我院共收入胃恶性肿瘤患者40例,将40例患者随机分为两组,每组各20例,保证两组患者在性别、年龄、胃癌分期等方面可比,无统计学差异(P＞0.05),标记为Ⅰ组和Ⅱ组。Ⅰ组20例患者于术前进行化疗干预,Ⅱ组在术中给予化疗干预。观察比较两组患者p53、ki-67表达状况及预后。结果 Ⅰ组及Ⅱ组治疗后p53及ki-67均比治疗前升高,差异有统计学意义(P<0.05)。但是治疗后,Ⅰ组和Ⅱ组的p53表达状况组间差异不明显,无统计学意义(P>0.05)。治疗前后,AI差异有统计学意义(P<0.05)。Ⅰ组效果明显好于Ⅱ组,两者差异有统计学意义(P <0.05)。术后六个月、一年随访时发现两组复发率、死亡率差别不大,无统计学意义(P>0.05),术后两年随访发现Ⅱ组复发率、死亡率明显低于Ⅰ组,差异有统计学意义(P<0.05)。结论术中化疗的疗效优于术前化疗,患者预后较术前化疗好。

关键词: 化疗, 进展期胃恶性肿瘤, p53, ki-67

Abstract: Objective To observe the effect of intraoperative and preoperative chemotherapy on the expression of p53, Ki-67 and prognosis in patients with advanced gastric cancer. Methods 40 cases of advanced gastric cancer in our hospital from Aug 2014 to May 2015 were enrolled in the study, and were divide into 2 groups randomly. In group I, 20 patients received chemotherapy intervention befoerer operation, and the other group received chemotherapy intervention during operation. The expressions and prognosis of p53 and Ki-67 were observed and compared between the two groups. Results Group Ⅰ and group Ⅱ after treatment, p53 and Ki-67 were higher than that before treatment, with statistical significance(P<0.05). However, there was no significant difference in the expression of p53 between group Ⅰ and group Ⅱ after treatment, and there was no significant difference(P>0.05). Before and after treatment, the difference of AI was significant, with statistical significance (P<0.05). The effect of group Ⅰ was obviously better than that of group Ⅱ, the difference was statistically significant(P<0.05). Six monthse after the operation and one year follow-up found two groups of recurrence rate and mortality rate had no significant difference(P>0.05). After two years follow-up found the group Ⅱ recurrence rate, mortality was lower than in group Ⅰ (P<0.05). Conclusion The effect of intraoperative chemotherapy is better than that of preoperative chemotherapy, and the prognosis is better than that of preoperative chemotherapy.

Key words: Chemotherapy, Advanced gastric cancer, p53, Ki-67

卢润豪. 术中及术前化疗干预对进展期胃恶性肿瘤手术患者p53、ki-67表达及预后影响的比较[J]. 广州医药, 2017, 48(5): 6-8.

LU Runhao. Intervention of preoperative and intraoperative chemotherapy influences on p53, Ki-67 expression and prognosis in patients with progressive stage gastric cancer[J]. Guangzhou Medical Journal, 2017, 48(5): 6-8.

参考文献

[1] 王晓娜. 胃癌预后因素的研究[D]. 天津:天津医科大学,2007.
[2] 李绮雯. 胃癌辅助放化疗预后预测因素及营养状态与治疗耐受性关系的研究[D]. 上海:复旦大学,2013.
[3] XIAO Q, PENG B, LAI Y, et al.Clinical comparison between intraoperative local arterial infusion chemotherapy and systemic venous chemotherapy of gastric cancer[J]. J West China Uni Med Sci, 2001,32(4):585-586; 608.
[4] WAKI T,TAMURA G,SATO M,et al.Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia[J]. Cancer Sci, 2003,94(4);360-364.
[5] 敖洪峰. 胃腺癌中c-erbB-2、CEA、p53、E-cadherin、Ki-67、Bax的表达及其临床病理意义[D]. 江西:南昌大学,2009.
[6] 黄利. p53蛋白和ki-67抗原在胃癌组织的表达及意义[D]. 安徽:安徽医科大学,2012.
[7] 何运胜,姜淮芜,汪盛贤,等. 进展期胃癌术中动脉化疗对p53和ki-67表达及细胞凋亡作用的影响[J]. 中国现代普通外科进展,2009,12(3):201-205.
[8] CHEONG J H,SHEN J Y, SONG C S,et al. Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer[J]. Ann Surg Oncol,2007,14(1):61-68.
[9] KODERA Y, FUJIWARA M, KOIKE M, et al. Chemotherapy as a component of multimodal therapy for gastric carcinoma[J]. World J Gastroenterol,2006,12(13): 2000-2005.
[10] 高登鹏,张霄成,石秀玲,等. 胃癌术中术后局部化疗对癌细胞及患者预后的影响[J]. 现代中西医结合杂志,2005,14(19):2535-2537.
[11] 田树波. MicroRNA-30b在胃癌中的功能及新辅助化疗应用于进展期胃癌的研究[D]. 北京:北京协和医学院,2015.
[12] 吴梅青. 新辅助化疗对腹腔镜局部进展期胃癌根治术围手术期及预后的影响[D]. 新疆:石河子大学,2014.
[13] 陈金元. FLEP新辅助化疗对胃癌患者免疫功能影响[D]. 广州:南方医科大学,2014.
[14] 任意. 胃癌临床病理资料的回顾性研究[D]. 天津:天津医科大学,2012.
[15] 李景武. 胃癌的外科治疗现状[D]. 天津:天津医科大学,2004.